Headquarters: Allschwil, Switzerland
CEO: Mr. Jean-Paul Clozel M.D.
CHF as of July 1, 2023
|Company||Market Cap (USD)|
|Novo Nordisk||$329.83 B|
|Vertex Pharmaceuticals Incorporated||$88.79 B|
|CSL Limited||$85.00 B|
|Marinomed Biotech AG||$84.73 B|
|Regeneron Pharmaceuticals, Inc.||$78.88 B|
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!